Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial
NCT06919380
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Anti-MDA5 Positive Dermatomyositis-Associated RP-ILD
Rapidly Progressive Interstitial Lung Disease
Interventions
DRUG:
MSC-exos Nebulization Therapy
Sponsor
Li Shiyue